MADRIGAL PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 113.24 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-07-30
- MADRIGAL PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 10.59K shares, a 62.25% decline year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 102.65K shares, a 3.48% increase year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 6.59K shares, a 21.13% decline year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 11.38K shares, a 16.00% decline year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 145.22K shares, a 15.01% decline from fiscal 2024.
- MADRIGAL PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 170.87K shares, a 449.23% increase from fiscal 2023.
- MADRIGAL PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 31.11K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 10.59K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | 113.24K shares 10-Q · filed 2026-07-30 | 119.83K shares derived: sum of 3 quarters · filed 2026-07-30 | 131.21K shares derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | 102.65K shares 10-Q · filed 2026-05-06 | 109.24K shares derived: sum of 2 quarters · filed 2026-05-06 | 120.62K shares derived: sum of 3 quarters · filed 2026-05-06 | 148.67K shares derived: sum of 4 quarters · filed 2026-05-06 |
| 2025-12-31 | 6.59K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | 17.97K shares derived: sum of 2 quarters · filed 2026-02-19 | 46.02K shares derived: sum of 3 quarters · filed 2026-02-19 | 145.22K shares 10-K · filed 2026-02-19 |
| 2025-09-30 | 11.38K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | 39.43K shares derived: sum of 2 quarters · filed 2025-11-04 | 138.63K shares 10-Q · filed 2025-11-04 | 146.98K shares derived: sum of 4 quarters · filed 2025-11-04 |
| 2025-06-30 | 28.05K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | 127.25K shares 10-Q · filed 2025-08-05 | 135.60K shares derived: sum of 3 quarters · filed 2025-08-05 | 149.15K shares derived: sum of 4 quarters · filed 2025-08-05 |
| 2025-03-31 | 99.20K shares 10-Q · filed 2025-05-01 | 107.56K shares derived: sum of 2 quarters · filed 2025-05-01 | 121.10K shares derived: sum of 3 quarters · filed 2025-05-01 | 134.56K shares derived: sum of 4 quarters · filed 2025-05-01 |
| 2024-12-31 | 8.36K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | 21.90K shares derived: sum of 2 quarters · filed 2025-02-26 | 35.35K shares derived: sum of 3 quarters · filed 2025-02-26 | 170.87K shares 10-K · filed 2025-02-26 |
| 2024-09-30 | 13.55K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | 27.00K shares derived: sum of 2 quarters · filed 2024-10-31 | 162.52K shares 10-Q · filed 2024-10-31 | |
| 2024-06-30 | 13.45K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | 148.97K shares 10-Q · filed 2024-08-07 | ||
| 2024-03-31 | 135.52K shares 10-Q · filed 2024-05-07 | |||
| 2023-12-31 | 31.11K shares 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |